Skip to search formSkip to main contentSkip to account menu

canagliflozin

Known as: Canagliflozin [Chemical/Ingredient] 
A C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity… 
National Institutes of Health

Related topics

Related topics

17 relations
24 HR canagliflozin 150 MG / Metformin hydrochloride 500 MG Extended Release Oral TabletIn BloodJNJ-24831754-ZAESodium-Glucose Transporter 2 Inhibitors [MoA]

Narrower (3)

Canagliflozin HemihydrateInvokametInvokana

Broader (1)

Hypoglycemic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
The Sweet Spot: Heart Failure Prevention with SGLT2 inhibitors.
2018
2018
Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
2018
2018
SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
2017
2017
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group…
Dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium glucose co‐transporter 2 (SGLT2) inhibitors are frequently used in… 
Review
2017
Review
2017
Cardiovascular disease leads to a new algorithm for diabetes treatment.
2016
2016
Development and Validation of a Stability-Indicating Reverse Phase HPLC-PDA Method for Determination of Canagliflozin in Bulk and Pharmaceutical Dosage Form
Objective: To develop and validate simple, authentic and stability indicating high performance liquid chromatographic method for… 
2015
2015
Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study
Background: The safety and efficacy of sodium glucose co-transporter 2 inhibitors in non-obese compared with obese patients with… 
2015
2015
An observational study of glycemic control in canagliflozin treated patients
Abstract Objective: To evaluate changes in glycemic control following the initial canagliflozin pharmacy claim in a real-world… 
2013
2013
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Review
2013
Review
2013
Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
Objective: To evaluate the available clinical data on canagliflozin and provide formulary considerations as to its place in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)